Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Generally, peptide therapy is a safe option when guided by a healthcare professional
Call the number above to learn more
Several important considerations apply: Individuals with active or severe gastrointestinal disease may experience worsening symptoms due to the gastrointestinal side effects of GLP-1 medications The slowed gastric emptying caused by these drugs could theoretically exacerbate symptoms in people with strictures or obstructive complications of Crohn's disease Weight loss associated with GLP-1 therapy may be inappropriate in patients with Crohn's disease who are already experiencing malnutrition or unintentional weight loss The interaction between GLP-1 medications and the inflammatory processes in IBD is not fully understood Clinical decision-making should involve a thorough assessment of disease activity, nutritional status, presence of complications (such as strictures or fistulas), and the primary indication for GLP-1 therapy
A new gastric juice peptide, BPC, heals both acute and chronic gastrointestinal lesions. Journal of Physiology (Paris), 95(1-6), 7992
US$ 27.22
US$ 20.37
US$ 23.88
US$ 29.43
